Galapagos (NASDAQ:GLPG)‘s stock had its “neutral” rating restated by stock analysts at UBS Group in a report issued on Monday, The Fly reports.
GLPG has been the subject of a number of other reports. Maxim Group lowered Galapagos from a “buy” rating to a “hold” rating in a research report on Wednesday, February 10th. Morgan Stanley decreased their price objective on Galapagos from $129.00 to $117.00 and set an “overweight” rating for the company in a report on Wednesday, March 17th. Citigroup cut Galapagos from a “buy” rating to a “neutral” rating in a report on Thursday, February 11th. Smith Barney Citigroup restated a “buy” rating on shares of Galapagos in a research note on Thursday, December 17th. Finally, Bryan, Garnier & Co lowered shares of Galapagos from a “buy” rating to a “sell” rating in a research note on Thursday, December 17th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the company’s stock. Galapagos currently has an average rating of “Hold” and an average price target of $150.08.
GLPG traded down $0.35 during midday trading on Monday, hitting $77.46. The company had a trading volume of 11,198 shares, compared to its average volume of 295,818. The stock’s 50 day moving average price is $81.48 and its 200 day moving average price is $107.65. Galapagos has a 52 week low of $74.51 and a 52 week high of $233.14. The company has a market capitalization of $5.07 billion, a price-to-earnings ratio of -11.72 and a beta of 0.76.
A number of institutional investors and hedge funds have recently made changes to their positions in GLPG. Comerica Bank lifted its holdings in Galapagos by 5.3% during the fourth quarter. Comerica Bank now owns 3,681 shares of the biotechnology company’s stock valued at $409,000 after purchasing an additional 185 shares during the last quarter. Northern Trust Corp raised its position in shares of Galapagos by 2.7% in the fourth quarter. Northern Trust Corp now owns 12,135 shares of the biotechnology company’s stock valued at $1,201,000 after purchasing an additional 322 shares during the period. LVW Advisors LLC lifted its stake in shares of Galapagos by 16.3% during the 4th quarter. LVW Advisors LLC now owns 2,472 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 347 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Galapagos by 13.3% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 3,602 shares of the biotechnology company’s stock valued at $511,000 after buying an additional 424 shares in the last quarter. Finally, RMR Wealth Builders bought a new position in Galapagos in the 4th quarter worth approximately $43,000. 11.17% of the stock is owned by institutional investors.
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, and psoriatic arthritis.
Read More: What is a short straddle?
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.